


# Explore Cereblon Modulation in Multiple Myeloma

Based on In Vitro Studies<sup>1-5</sup>

Tap to learn how cereblon-modulating agents exert their tumoricidal activity



Tap to learn how cereblon-modulating agents exert their immune stimulatory activity

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



HOME

# Role of Oncogenes in Myeloma Cell Activity

Based on In Vitro Studies




IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD<sup>®</sup> and CELMoD<sup>®</sup> are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.  
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21


[References](#)





# Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies



Preclinical studies have demonstrated that targeting Ikaros and Aiolos for degradation resulted in decreased expression of *IRF4* and *c-MYC*. This led to tumoricidal effects in myeloma cells.<sup>13</sup>

IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.


The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.



HOME

# Cereblon Modulation Inside a Myeloma Cell

Based on In Vitro Studies






HOME

# T-Cell Activity in Multiple Myeloma

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD<sup>®</sup> and CELMoD<sup>®</sup> are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.  
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21


[References](#)



HOME

# Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD<sup>®</sup> and CELMoD<sup>®</sup> are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.  
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21


[References](#)



HOME

# Cereblon Modulation Inside a T Cell

Based on In Vitro Studies



IMiDs belong to the class of cereblon E3 ligase modulators. While they have a shared target with novel agents such as iberdomide and CC-92480, their downstream effects differ.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

IMiD<sup>®</sup> and CELMoD<sup>®</sup> are registered trademarks of Celgene Corporation, a Bristol Myers Squibb Company.  
© 2021 Bristol-Myers Squibb Company. All rights reserved. VV-MED-01745 04/21